Stevanato Group to open US Technology Excellence Center in Boston
![](/46/pdcnewsitem/08/34/97/Stevanato%20Group%20-%20TEC%20Center%20(1).jpg)
US TEC will support biopharma drug development throughout the lifecycle, helping them overcome the challenges of the container-closure system.
Italian-based Stevanato Group, a producer of pharmaceutical glass containers and integrated provider of drug delivery systems, is preparing to open its Technology Excellence Center in Boston (US TEC), Massachusetts.
The new center will provide a full-service to support biopharmaceutical companies along their drug development journey, from the early phase to commercialization and lifecycle management, helping them to overcome the challenges of the container-closure system.
The technology and knowledge transfer from the Italian laboratory will be finalized later this year.
US TEC will support one of the most binding decisions for biopharma industry players: how to select the optimum glass container. Making the right choice during the early-stage of product development ensures two-fold compatibility: drug and container closure system, as well as container closure system integration into drug delivery devices.
"From its outset, the US TEC will advise on materials science, chemistry, and engineering performing many added value analytical tests focusing on container closure characterization as well as fill & finish development and optimization. In the second phase, we will be adding customized solutions dedicated to product development and functional testing of primary containers and drug delivery devices," said Paolo Patri, Stevanato Group Chief Technology Officer.
To support today's increasingly urgent need for treatments and vaccines related to COVID-19, Stevanato Group has deployed all its available assets to ensure the availability of state-of-the-art glass vials and syringes, plastics diagnostic consumables, equipment, and analytical testing.
"As pharma companies are under pressure to find more effective and safer treatments rapidly, more clinical trials take place, and new emerging therapies are developed and tested. Being in the US, we can offer timely solutions for robust product development for these therapies," said Abizer Harianawala, Site Leader at Stevanato Group's US TEC.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance